About Evox Therapeutics
Evox Therapeutics is a company based in Oxford (United Kingdom) founded in 2016 by Samir El Andaloussi, Matthew Wood, and Per Lundin. Evox Therapeutics has raised $155.79 million across 6 funding rounds from investors including Gov.uk, TD Securities and Gates Foundation. The company has 58 employees as of December 31, 2024. Evox Therapeutics offers products and services including ExoEdit Technology and Therapeutics Pipeline. Evox Therapeutics operates in a competitive market with competitors including Harmony Biosciences, QurAlis, Passage Bio, Longboard Pharmaceutical and Autobahn Therapeutics, among others.
- Headquarter Oxford, United Kingdom
- Employees 58 as on 31 Dec, 2024
- Founders Samir El Andaloussi, Matthew Wood, Per Lundin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evox Therapeutics Limited
- Date of Incorporation 22 Mar, 2016
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
$11.46 M (USD)29as on Dec 31, 2023
-
Net Profit
-$15.11 M (USD)11as on Dec 31, 2024
-
EBITDA
-$18.81 M (USD)14as on Dec 31, 2024
-
Total Equity Funding
$155.79 M (USD)
in 6 rounds
-
Latest Funding Round
$95.97 M (USD), Series C
Feb 16, 2021
-
Investors
Gov.uk
& 11 more
-
Employee Count
58
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evox Therapeutics
Evox Therapeutics offers a comprehensive portfolio of products and services, including ExoEdit Technology and Therapeutics Pipeline.
Delivers CRISPR-based gene editing via exosomes for disease treatment
Advances therapies for neurological diseases through exosome nanoparticles
People of Evox Therapeutics
Unlock access to complete
Senior Team
9 people
Leadership Team
7 people
Scientific Team
6 people
Research Team
4 people
Board Team
3 people
Product Management Team
3 people
Human Resources and Administration
2 people
Principal Team
2 people
Unlock access to complete
Funding Insights of Evox Therapeutics
Evox Therapeutics has successfully raised a total of $155.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $95.97 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evox Therapeutics
Evox Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, TD Securities and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Investment management services for science ventures are provided in Oxford.
|
Locked | Locked | Locked |
Investor details for Evox Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evox Therapeutics
Investment portfolio details for Evox Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evox Therapeutics
Detailed financials for Evox Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evox Therapeutics Comparisons
Peer comparison for Evox Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evox Therapeutics
Evox Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, QurAlis, Passage Bio, Longboard Pharmaceutical and Autobahn Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Gene therapies for CNS rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for rare neurological diseases are developed.
|
|
| Locked | Locked | Locked |
CNS therapeutics are developed via regenerative medicine for disorders.
|
Detailed competitors of Evox Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evox Therapeutics
Complete news archive for Evox Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evox Therapeutics
Evox Therapeutics was founded in 2016.
Evox Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Per Lundin is the current CEO of Evox Therapeutics. They have also founded this company.
Evox Therapeutics is a funded company, having raised a total of $155.79M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Evox Therapeutics is 58.
Annual revenue of Evox Therapeutics is $11.46M as on Dec 31, 2023.
Evox Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Exosome-based therapies are developed to address neurological diseases through a proprietary CRISPRCas gene editing system encapsulated in exosomes. Genes such as ATXN2, linked to Spinocerebellar Ataxia type 2 and Amyotrophic Lateral Sclerosis, and MSH3, associated with Huntingtons disease and triplet repeat disorders, are targeted in the pipeline. Operations focus on gene modification for neurodegenerative conditions.
Evox Therapeutics's top competitors include Harmony Biosciences, QurAlis and MindMed.
Evox Therapeutics offers ExoEdit Technology and Therapeutics Pipeline.
Evox Therapeutics has 12 investors. Key investors include Gov.uk, TD Securities, Gates Foundation, Orbimed, and Oxford University Innovation.